TANGO: Post-Hoc Analysis of Viral Replication for 2-Drug DTG/3TC Regimen vs 3- or 4-Drug TAF-Based Regimen Through Week 96

July 18-21, 2021; Virtual
Patients with HIV-1 RNA <40 copies/mL and target not detected outcome similar with dual DTG/3TC vs triple or quadruple TAF-based regimens.
Format: Microsoft PowerPoint (.ppt)
File Size: 230 KB
Released: July 22, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Slides from Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 26, 2022

Clinical Care Options (CCO) expert insight by Dr Gail Matthews on what to consider when switching suppressed patients with HIV/HBV from oral to long-acting ART regimen

person default Prof Gail Matthews, MD, PhD Released: January 25, 2022

Slides from Dr John Baxter and Clinical Care Options (CCO): Proviral genotyping may help to inform ART choice in experienced patients who are suppressed

John D. Baxter, MD Released: January 24, 2022

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings